Session Description:

Alzheimer’s disease (AD) diagnostics have come a long way from the days of PET scans and magnetic resonance imaging. While brain imaging remains an important part of the diagnostic process, advances in omics technologies and computational capabilities have made it possible to test for molecular markers of AD such as amyloid-beta isoform 42 and phosphorylated tau found in cerebrospinal fluid. But progress does not stop there. The next step in the evolution of AD research is identifying noninvasive or minimally invasive molecular markers that can be readily extracted from bodily fluids like blood, plasma, serum, urine, and saliva. These are the markers that will serve as the foundation for the development of the next generation of highly accurate diagnostic methodologies for AD detection and monitoring. In this Product Theater Presentation, moderated Mike Miller, SVP, Accelerator and Clinical Services, Dr. Blaine R. Roberts will discuss the history of AD biomarker research and offer insights into where the field is headed next. The speakers will discuss the historical milestones that have shaped the current understanding of this neurodegenerative disorder, and the broader implications for cognitive health, as well as the transformative role of emerging biomarkers like plasma p-Tau181 and p-Tau 217 in the early detection, prognosis, and ongoing monitoring of AD, and their potential application in clinical contexts.